Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Fagron NV: Disclosure of received notification

Fagron NV
Posted on: 31 Aug 18

Regulated information
Nazareth (Belgium)/Rotterdam (the Netherlands), 31 August 2018

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.

Notification of Adrianus van Herk, received on 28 August 2018

  • On 28 August 2018, Fagron received a notification that the shareholding of Adrianus van Herk, a person that notifies alone, had fallen below the disclosure threshold of 3% on 27 August 2018 as the result of the disposal of voting securities or voting rights.
  • The notification of Adrianus van Herk can be viewed on investors.fagron.com via this link .

In case of differences between the English translation and the Dutch original of this press release, the latter will prevail.

For more information
Constantijn van Rietschoten
Chief Communications Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
investors.fagron.com

Fagron profile
Fagron is a leading global company active in pharmaceutical compounding and focused on delivering personalized pharmaceutical care to hospitals, pharmacies, clinics and patients in 35 countries worldwide.

The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam (stock market code 'FAGR'). The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

Disclosure of received notification


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Fagron NV via GlobeNewswire
HUG#2213437
GlobeNewswire
globenewswire.com

Last updated on: 01/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.